Global Protein Kinase Inhibitor Market
Global Protein Kinase Inhibitor Market

Protein Kinase Inhibitor Comprehensive Study by Type (Serine/Threonine Protein Kinase Inhibitors, Tyrosine Protein Kinase Inhibitor), Application (Lung Cancer, Breast Cancer, Renal Cell Cancer, Others), End Use (Therapeutic, Diagnostic, Research), End User (Pharmaceutical companies, Private and Government research institutes, Academic Institutes, Healthcare facilities) Players and Region - Global Market Outlook to 2026

Protein Kinase Inhibitor Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 201 Pages 183 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Protein Kinase Inhibitor Market Overview:
Protein kinase is an enzyme that moves phosphate from ATP (Adenosine Triphosphate) to the protein structure and rearranges it. It controls a wide range of cell functions, including cell cycle, proliferation, apoptosis, and differentiation. In cancer, these cell processes are used to control a number of cell activities.A protein kinase inhibitor is a type of enzyme inhibitor that inhibits the activity of one or more protein kinases and is thought to be useful in preventing cancerous cell development. When the number of cancer patients grows, so does the need for new treatments. According to the World Health Organization (WHO), cancer took the lives of 9.6 million people worldwide in 2018. Furthermore, over the forecasted era, demand for kinase inhibitors is expected to be driven by increasing healthcare infrastructure in emerging economies and a focus on advanced cancer treatment.

Growth Drivers
  • Increasing Number of Cancer Patients
  • Rising Applications of Kinase Inhibitors in Cancer Therapies

Market Trends
  • Rising Adoption of Advanced Technologies for Cancer Treatment
  • Technological Advancement in the Healthcare Industry

Roadblocks
  • Stringent Government Regulations Regarding Approval Procedure
  • High Cost of Cancer Treatment

Opportunities
  • Rise in Number of Clinical Trials
  • Increasing Demand from the Developing Economies

Challenges
  • Lack of Advanced Healthcare Infrastructure in the Low and Middle Income Group Countries


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Roche Holding AG (Switzerland), Novartis (Switzerland), AstraZeneca (United Kingdom), Bayer (Germany), Pfizer (United States), GlaxoSmithKline (United Kingdom), Bristol-Myers Squibb (United States), Cytrx Corporation (United States), Eisai Inc. (United States) and Merck Serono SA (Switzerland). Additionally, following companies can also be profiled that are part of our coverage like Eton Bioscience Inc. (United States) and Inhibikase Therapeutics, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Protein Kinase Inhibitor market by 2026. Considering Market by End Use, the sub-segment i.e. Therapeutic will boost the Protein Kinase Inhibitor market. Considering Market by End User, the sub-segment i.e. Pharmaceutical companies will boost the Protein Kinase Inhibitor market.

“The US FDA has approved 48 small molecule protein kinase inhibitors, nearly all of which are orally effective with the exceptions of netarsudil (which is given as an eye drop) and temsirolimus (which is given intravenously). Of the 48 approved drugs, the majority (25) target receptor protein-tyrosine kinases, ten target non-receptor protein-tyrosine kinases, and 13 target protein-serine/threonine protein kinases.”

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Protein Kinase Inhibitor market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Protein Kinase Inhibitor market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Research Organizations, Potential Investors, Government Regulatory Authorities, Research and Development Companies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Serine/Threonine Protein Kinase Inhibitors
  • Tyrosine Protein Kinase Inhibitor
By Application
  • Lung Cancer
  • Breast Cancer
  • Renal Cell Cancer
  • Others
By End Use
  • Therapeutic
  • Diagnostic
  • Research

By End User
  • Pharmaceutical companies
  • Private and Government research institutes
  • Academic Institutes
  • Healthcare facilities

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Cancer Patients
      • 3.2.2. Rising Applications of Kinase Inhibitors in Cancer Therapies
    • 3.3. Market Challenges
      • 3.3.1. Lack of Advanced Healthcare Infrastructure in the Low and Middle Income Group Countries
    • 3.4. Market Trends
      • 3.4.1. Rising Adoption of Advanced Technologies for Cancer Treatment
      • 3.4.2. Technological Advancement in the Healthcare Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global Protein Kinase Inhibitor, by Type, Application, End Use, End User and Region (value) (2015-2020)
    • 5.1. Introduction
  • 6. Protein Kinase Inhibitor: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. Roche Holding AG (Switzerland)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Novartis (Switzerland)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. AstraZeneca (United Kingdom)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. Bayer (Germany)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. Pfizer (United States)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. GlaxoSmithKline (United Kingdom)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Bristol-Myers Squibb (United States)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. Cytrx Corporation (United States)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. Eisai Inc. (United States)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. Merck Serono SA (Switzerland)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
  • 7. Global Protein Kinase Inhibitor Sale, by Type, Application, End Use, End User and Region (value) (2021-2026)
    • 7.1. Introduction
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Company Basic Information, Sales Area and Its Competitors
  • Table 2. Company Basic Information, Sales Area and Its Competitors
  • Table 3. Company Basic Information, Sales Area and Its Competitors
  • Table 4. Company Basic Information, Sales Area and Its Competitors
  • Table 5. Company Basic Information, Sales Area and Its Competitors
  • Table 6. Company Basic Information, Sales Area and Its Competitors
  • Table 7. Company Basic Information, Sales Area and Its Competitors
  • Table 8. Company Basic Information, Sales Area and Its Competitors
  • Table 9. Company Basic Information, Sales Area and Its Competitors
  • Table 10. Company Basic Information, Sales Area and Its Competitors
  • Table 11. Research Programs/Design for This Report
  • Table 12. Key Data Information from Secondary Sources
  • Table 13. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 5. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 6. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 7. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 8. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 9. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 10. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 11. Bayer (Germany) Revenue: by Geography 2020
  • Figure 12. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 13. Pfizer (United States) Revenue: by Geography 2020
  • Figure 14. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 15. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 16. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 17. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 18. Cytrx Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Cytrx Corporation (United States) Revenue: by Geography 2020
  • Figure 20. Eisai Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Eisai Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Merck Serono SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Merck Serono SA (Switzerland) Revenue: by Geography 2020
Some of the key companies/manufacturers profiled in the report
  • Roche Holding AG (Switzerland)
  • Novartis (Switzerland)
  • AstraZeneca (United Kingdom)
  • Bayer (Germany)
  • Pfizer (United States)
  • GlaxoSmithKline (United Kingdom)
  • Bristol-Myers Squibb (United States)
  • Cytrx Corporation (United States)
  • Eisai Inc. (United States)
  • Merck Serono SA (Switzerland)
Additional players considered in the study are as follows:
Eton Bioscience Inc. (United States) , Inhibikase Therapeutics, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation